MA29787B1 - Traitement de maladies auto-immunes - Google Patents

Traitement de maladies auto-immunes

Info

Publication number
MA29787B1
MA29787B1 MA30758A MA30758A MA29787B1 MA 29787 B1 MA29787 B1 MA 29787B1 MA 30758 A MA30758 A MA 30758A MA 30758 A MA30758 A MA 30758A MA 29787 B1 MA29787 B1 MA 29787B1
Authority
MA
Morocco
Prior art keywords
autoimmune diseases
treatment
methods
sclerosis
ureity
Prior art date
Application number
MA30758A
Other languages
English (en)
Inventor
Rainer Albert
Nigel Graham Cooke
Barbara Nuesslein-Hildesheim
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29787B1 publication Critical patent/MA29787B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'INVENTION PORTE SUR DES MÉTHODES DE TRAITEMENT DE DIVERSES MALADIES AUTO-IMMUNES, TELLES QUE LA SCLÉROSE EN PLAQUE, LA NÉVRITE PÉRIPHÉRIQUE, LA NÉVRITE OPTIQUE, LA SCLÉROSE AMYOTROPHIQUE LATÉRALE ET L'UVÉITE, CES MÉTHODES UTILISANT DES DÉRIVÉS AMINO-ALCOOL SPÉCIFIQUES.
MA30758A 2005-09-09 2008-03-17 Traitement de maladies auto-immunes MA29787B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09

Publications (1)

Publication Number Publication Date
MA29787B1 true MA29787B1 (fr) 2008-09-01

Family

ID=37056992

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30758A MA29787B1 (fr) 2005-09-09 2008-03-17 Traitement de maladies auto-immunes

Country Status (28)

Country Link
US (1) US20080200438A1 (fr)
EP (2) EP1926483B1 (fr)
JP (4) JP5244598B2 (fr)
KR (3) KR20140117704A (fr)
CN (1) CN101257899B (fr)
AT (1) ATE489948T1 (fr)
AU (2) AU2006289100B2 (fr)
BR (1) BRPI0615906A2 (fr)
CA (2) CA2620554C (fr)
CY (1) CY1111285T1 (fr)
DE (1) DE602006018629D1 (fr)
DK (2) DK2295049T3 (fr)
ES (2) ES2357426T3 (fr)
IL (2) IL189665A (fr)
JO (1) JO2655B1 (fr)
MA (1) MA29787B1 (fr)
MX (1) MX2008003170A (fr)
NO (1) NO20081727L (fr)
NZ (2) NZ588372A (fr)
PL (2) PL2295049T3 (fr)
PT (2) PT2295049E (fr)
RU (2) RU2493840C2 (fr)
SG (1) SG165364A1 (fr)
SI (2) SI2295049T1 (fr)
TN (1) TNSN08103A1 (fr)
TW (2) TWI372620B (fr)
WO (1) WO2007028821A2 (fr)
ZA (1) ZA200801694B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014329B (zh) 2004-07-16 2010-09-08 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
EP1806338B1 (fr) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Procédé de synthèse de l hydrochlorure de 2-amino-2-[2-[4-(3-benzyloxy-phénylthio)-2-chlorophényl[éthyl]-1,3-propanediol et des hydrates de ce composé, et intermédiaires de synthèse de celles-ci
SI1932522T1 (sl) * 2005-10-07 2012-08-31 Kyorin Seiyaku Kk Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
MX2009001457A (es) * 2006-08-08 2009-02-19 Kyorin Seiyaku Kk Derivados de aminoalcohol e inmunosupresores que contienen lo mismo como ingrediente activo.
JP5188972B2 (ja) * 2006-08-08 2013-04-24 杏林製薬株式会社 アミノリン酸エステル誘導体及びそれらを有効成分とするｓ１ｐ受容体調節剤
WO2008099781A1 (fr) * 2007-02-13 2008-08-21 Kyorin Pharmaceutical Co., Ltd. Agent thérapeutique ou prophylactique pour une maladie démyélinisante comprenant un dérivé d'amino alcool comme ingrédient actif
WO2009099174A1 (fr) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. Agent thérapeutique ou agent préventif pour maladie inflammatoire des intestins contenant un dérivé d'alcool aminé comme composant actif
NZ589412A (en) * 2008-05-20 2012-11-30 Kyorin Seiyaku Kk Use of a sphingosine-1-phosphate (S1P) agonist for maintance of induced remission of autoimmune or inflammatory diseases after inital treatment
CN102119028A (zh) * 2008-08-18 2011-07-06 诺瓦提斯公司 用于治疗脱髓鞘性周围神经病的氨基醇衍生物
EP2566473B1 (fr) * 2010-05-06 2016-01-06 Novartis AG Posologie de dérivés de sulfure de diaryle
MX2012012926A (es) * 2010-05-06 2012-12-17 Novartis Ag Tratamiento de enfermedades autoinmunes.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
DE69840169D1 (de) * 1997-02-27 2008-12-11 Novartis Ag Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
EP1431275B1 (fr) * 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur
MXPA04002679A (es) * 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
KR101003877B1 (ko) * 2002-09-19 2010-12-30 교린 세이야꾸 가부시키 가이샤 아미노알코올 유도체와 그 부가염 및 면역 억제제
KR20080103117A (ko) * 2002-09-24 2008-11-26 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
EP1542662A1 (fr) * 2002-09-28 2005-06-22 McNEIL-PPC, INC. Forme galenique a liberation immediate comprenant une capsule pourvue d'orifices
US7456157B2 (en) * 2003-02-18 2008-11-25 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivatives, addition salts thereof and S1P receptor modulators
CA2521325C (fr) * 2003-04-08 2010-09-14 Novartis Ag Compositions pharmaceutiques solides comprenant un agoniste des recepteurs de la s1p et un alcool de sucre
TW200505416A (en) * 2003-08-12 2005-02-16 Mitsubishi Pharma Corp Bi-aryl compound having immunosuppressive activity
CN1874996B (zh) * 2003-08-28 2011-05-18 诺瓦提斯公司 氨基丙醇衍生物
CN101014329B (zh) * 2004-07-16 2010-09-08 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
KR20140095109A (ko) * 2004-11-29 2014-07-31 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2015025002A (ja) 2015-02-05
TWI376223B (en) 2012-11-11
RU2493840C2 (ru) 2013-09-27
AU2010224355A1 (en) 2010-10-14
AU2006289100B2 (en) 2010-07-22
KR20140117704A (ko) 2014-10-07
CY1111285T1 (el) 2015-08-05
EP2295049B1 (fr) 2014-11-26
SI2295049T1 (sl) 2015-03-31
PT1926483E (pt) 2011-03-03
EP1926483B1 (fr) 2010-12-01
DK1926483T3 (da) 2011-03-14
NO20081727L (no) 2008-06-06
KR101476451B1 (ko) 2014-12-24
WO2007028821A3 (fr) 2007-05-03
PL2295049T3 (pl) 2015-04-30
JP6077265B2 (ja) 2017-02-08
PT2295049E (pt) 2015-03-02
TW201034659A (en) 2010-10-01
IL189665A0 (en) 2008-06-05
BRPI0615906A2 (pt) 2011-05-31
CA2820510A1 (fr) 2007-03-15
AU2010224355B2 (en) 2012-03-29
HK1149906A1 (en) 2011-10-21
TNSN08103A1 (en) 2009-07-14
SI1926483T1 (sl) 2011-04-29
CN101257899B (zh) 2012-10-03
ZA200801694B (en) 2009-09-30
JP2009507810A (ja) 2009-02-26
RU2424795C2 (ru) 2011-07-27
MX2008003170A (es) 2008-03-18
DE602006018629D1 (de) 2011-01-13
IL233328A0 (en) 2014-08-31
TWI372620B (en) 2012-09-21
EP2295049A1 (fr) 2011-03-16
DK2295049T3 (en) 2015-02-23
EP1926483A2 (fr) 2008-06-04
PL1926483T3 (pl) 2011-05-31
WO2007028821A2 (fr) 2007-03-15
KR101476591B1 (ko) 2014-12-24
US20080200438A1 (en) 2008-08-21
CN101257899A (zh) 2008-09-03
TW200803829A (en) 2008-01-16
IL189665A (en) 2014-07-31
ATE489948T1 (de) 2010-12-15
JP2013010802A (ja) 2013-01-17
JP2017019854A (ja) 2017-01-26
JP5244598B2 (ja) 2013-07-24
RU2008113187A (ru) 2009-10-20
ES2529724T3 (es) 2015-02-25
CA2620554C (fr) 2013-12-17
NZ566137A (en) 2011-05-27
ES2357426T3 (es) 2011-04-26
AU2006289100A1 (en) 2007-03-15
NZ588372A (en) 2012-03-30
KR20080046231A (ko) 2008-05-26
RU2011111117A (ru) 2012-09-27
JO2655B1 (en) 2012-06-17
SG165364A1 (en) 2010-10-28
KR20140019033A (ko) 2014-02-13
CA2620554A1 (fr) 2007-03-15

Similar Documents

Publication Publication Date Title
MA29787B1 (fr) Traitement de maladies auto-immunes
BRPI0511875A (pt) uso de compostos de peptìdeo para tratamento da esclerose lateral amiotrófica
DK1754707T3 (da) Multicykliske forbindelser og anvendelse deraf som inhibitorer af PARP-, VEGFR2- og MLK3-enzymer
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
ATE368031T1 (de) Neue gamma secretase inhibitoren
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
UY26813A1 (es) Compuestos para tratar enfermedad de alzheimer
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
EP1689713A4 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
BRPI0408491A (pt) tratamento da doença de alzheimer
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
MA29587B1 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
MXPA05009718A (es) Uso de un fibrato y orlistato para el tratamiento de obesidad.
EA200800890A1 (ru) Модуляторы гексагидроциклогептапиразол каннабиноида
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
ECSP034684A (es) Uso de 2-amino-1-(4-hidroxi-2-metanosulfonamidofenil)etanol para tratar la incontinencia urinaria
BR0309110A (pt) composições e processo de tratamento da doença de alzheimer
CY1116051T1 (el) Θεραπεια αυτοανοσων ασθενειων
EA200600534A1 (ru) Сочетание ингибитора обратного захвата серотонина и амоксапина